Suresnes, January 2, 2024 – 6 p.m. CET – –
Néovacs (Euronext Growth Paris: ALNEV), a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases, presents the number of shares and voting rights making up the share capital, in accordance with the provisions of article L.233-8 II of the Commercial Code and article 223-16 of the General Regulations of the Financial Markets Authority.
|
Date |
Number of shares making up the capital |
Number of GROSS voting rights |
Number of NET voting rights |
12/31/2023 | 3,516,842,552 | 3,516,842,552 | 3,516,842,552 |
Furthermore, the company recalls that, since 1
er
January 2023, the number of shares issued each month by the company breaks down as follows:
|
Wording |
OCEANE |
ORA |
TOTAL |
|
Before regrouping | |||
January-23 | 348,132,988 | 348,132,988 | |
February-23 | 295 370 368 | 295 370 368 | |
March-23 | 931 876 528 | 931 876 528 | |
April-23 | 4,388,888,222 | 4,388,888,222 | |
May-23 | 0 | 0 | |
|
After grouping | |||
June-23 | 622 278 | 622 278 | |
July-23 | 813 514 | 155,909 | 969,423 |
Aug-23 | 5,648,423 | 1,074,666 | 6,723,089 |
September-23 | 196,671,818 | 83,989,996 | 280,661,814 |
October-23 | 431 592 047 | 186 315 475 | 617 907 522 |
November-23 | 444 444 444 | 256 357 142 | 700 801 586 |
December-23 | 1,666 666 666 | 241,714,283 | 1,908,380,949 |
As a reminder, the permanent monitoring of the creation of new shares resulting in particular from the conversions of OCEANEs and BSA exercises
E
is the subject of summary tables that are systematically updated and available on the NEOVACS website.
ABOUT NEOVACS
Néovacs is a French biotechnology company which conducts a dual activity of R&D and investment. Its own products are vaccine candidates developed from its kinoid® technology platform in lupus and allergies. The innovative approach uses the patient’s immune system to regulate harmful overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. At the same time, the Company uses its internal expertise to invest in innovative Biotech and Medtech companies with high potential.
For more information :
www.neovacs.fr
Jérôme FABREGUETTES LEIB | Anne-Charlotte DUDICOURT |
Warning :
The company Néovacs has set up (i) financing in the form of OCEANE-BSA with the company European High Growth Opportunities Securitization Fund, which, after receiving the shares resulting from the conversion or exercise of these instruments, n is not intended to remain a shareholder of the company, and (ii) financing in ORA which have all been transferred to a trust, which is now responsible for their equitization.
The shares resulting from the conversion or exercise of the above-mentioned securities are generally sold in the market at very short notice, which can create strong downward pressure on the share price. In the specific case of the trust, the shares are sold on the market according to the terms set out in the trust agreement.
Shareholders may suffer a loss of their invested capital due to a significant decrease in the value of the company’s stock, as well as significant dilution due to the number of securities issued to the company European High Growth Opportunities Securitization Fund and/or trust.
Investors are advised to be very vigilant before making the decision to invest (or remain invested) in the securities of the company admitted to trading which carries out such dilutive financing transactions, particularly when they are carried out successively. The company recalls that this dilutive financing operation is not the first that it has implemented.
[1]
Consolidation occurred on June 2, 2023 through the exchange of 8,000 old shares for 1 new share
This publication has the “🔒 Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
yG5vYpdnlpqdnmtrZJtlb5KYaZdpm2SdmGedx2OblsfJb2tllpxhl5qeZnFkmW5r
– To control this key:
https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
– Information relating to the total number of voting rights and shares making up the capital
Full and original press release in PDF format:
https://www.actusnews.com/news/83495-2024.01.02_nvcs_cp_ddv_decembre_2023.pdf
© Copyright Actusnews Wire
Receive future company press releases free of charge by email by subscribing to www.actusnews.com